VivoSeq
Immunology

Atopic Dermatitis

377

Pipeline Programs↗

156

Active Trials↗

156

Companies Involved↗

Atopic Dermatitis is a highly competitive landscape with 377 programs across 156 companies. The most active players are Innovent Biologics (Suzhou) Co. Ltd., Attovia Therapeutics Inc, Asana BioSciences. 46 therapies are approved with 50 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

92/100

Pipeline Velocity

75/100

Mech. Concentration

13/100

Completion Rate

84/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

2 programs

Phase 1A

Attovia Therapeutics Inc

2 programs

Phase 1A

Asana BioSciences

1 program

Phase 1A

ASLAN Pharmaceuticals

1 program

Phase 1Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.

1 program

Phase 1H

Hangzhou Highlightll Pharmaceutical Co., Ltd

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

91%

Small molecule

401 of 441 classified programs — the dominant modality here.

9%ALL OTHERSMonoclonal antibody286%Protein / enzyme61%Vaccine61%

Small molecule leads; the ring shows all 441 classified programs, each share of the total. Modality classified for 96% of 509 pipeline programs.

Analysis

Trial Status

812

clinical trials

Completed515 · 63%
Recruiting77 · 9%
Terminated66 · 8%
Unknown status44 · 5%
Active, not recruiting41 · 5%
Not yet recruiting34 · 4%
Other35 · 4%

Clinical Trials

Trial Activity

812 trials

Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact
Recruiting·UUniversity Hospital Schleswig-Holstein·N/A·NCT07444801·30 enrolled
A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
Recruiting·SShanghai Qilu Pharmaceutical Research and Development Center LTD·Phase 1·NCT06946641·102 enrolled
Replication of the Heads Up Atopic Dermatitis Trial With Registry Data
Recruiting·TTechnische Universität Dresden·N/A·NCT06937788·240 enrolled
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
Recruiting·BBrexogen Inc.·Phase 1·NCT06055361·45 enrolled
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Recruiting·AbbVie logoAbbVie·Phase 3·NCT06461897·675 enrolled
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
Recruiting·Pfizer logoPfizer·N/A·NCT06899204·150 enrolled
Drug Survival of Target Therapies in Atopic Dermatitis
Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT06882148·1,167 enrolled
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Recruiting·Pfizer logoPfizer·Phase 2·NCT05995964·340 enrolled
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
Recruiting·IInstituto de Investigación Hospital Universitario La Paz·Phase 4·NCT06366932·150 enrolled
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
Recruiting·Eli Lilly logoEli Lilly·Phase 4·NCT07006792·200 enrolled
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
Recruiting·OOneness Biotech Co., Ltd.·Phase 2·NCT06397911·90 enrolled
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
Recruiting·AAttovia Therapeutics Inc·Phase 1·NCT07205081·72 enrolled
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
Recruiting·BBluefin Biomedicine, Inc.·Phase 2·NCT07105488·225 enrolled
Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
Recruiting·KKeymed Biosciences Co.Ltd·Phase 2·NCT06947980·200 enrolled
Herbal Ointment in Treating Atopic Dermatitis Topically
Recruiting·EEn Chu Kong Hospital·Phase 2/3·NCT06850311·66 enrolled
Page 1 of 55

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)